Image source: Volodymyr Hryshchenko on Unsplash
Clinical research is at a turning point. Thanks to big data and modern analytics, studies can be conducted faster, more targeted, and more securely. This results in strategic advantages for pharmaceutical companies and exciting roles for professionals at the intersection of life sciences, data science, and IT. At the same time, companies must ensure that data is handled responsibly, which is particularly important in Europe.
According to recent studies, the global market for big data in healthcare and pharmaceuticals is estimated at USD 56.44 billion in 2025 and is expected to grow to USD 275.44 billion by 2034.
The broader market for life science analytics, which includes big data, AI, and predictive analytics, is also growing rapidly: According to Kings Research, it is expected to increase from USD 33.09 billion in 2023 to USD 96.19 billion in 2031.
In addition, Straits Research forecasts growth in the healthcare big data sector from USD 50.74 billion in 2024 to USD 145.42 billion in 2033. The average annual growth rate is around 16.7%.
These figures make it clear that big data is not just a technical issue for pharmaceutical companies seeking to optimize their research, clinical development, and market access in a data-driven manner, but also a strategic driver.
Clinical trials are traditionally considered time-consuming and costly. However, the global market for clinical trials is growing significantly: according to BioSpace, it will increase to USD 149.58 billion by 2034 (CAGR ~ 6.1%).
At the same time, the market for analytics platforms is also growing. The market for clinical data analytics solutions was valued at USD 5.9 billion in 2023 and is expected to grow significantly by 2032.
These platforms enable real-time monitoring, predictive analytics, and adaptive study designs. This leads to shorter study durations, fewer dropouts, and better resource utilization.
AI is playing an increasingly important role in clinical trials. According to Precedence Research, the market for “AI in clinical trials” will grow from USD 2.60 billion in 2025 to USD 22.36 billion in 2034 (CAGR ~ 27%).
With the help of technologies such as deep learning, it is possible to stratify patients, predict risk events, and dynamically adapt study designs.
Such predictive models can be used to apply inclusion and exclusion criteria more efficiently, automate screening processes, and identify relevant participant groups more quickly.
Big data opens up new avenues for personalized medicine. By combining molecular data (such as genomic data) with clinical parameters and real-world evidence (RWE), therapies can be developed in an even more targeted manner.
At the same time, expanded data sets improve pharmacovigilance: continuous monitoring from various sources (apps, registries, electronic health records) enables safety risks to be identified at an early stage.
At the same time, research findings show how network effects in clinical studies force many trials to focus on already known targets. This challenge can be mitigated by data-based strategies.
In addition to technical expertise, a well-thought-out governance structure is also required for the successful use of big data in clinical research. Companies must define roles.
At the same time, data protection must not be neglected. In Europe in particular, the processing of medical data requires strict compliance with the GDPR. Key aspects here are informed consent, pseudonymization, and data minimization.
Companies should develop a clear data strategy, establish documented processes for data use, and involve regulatory expertise at an early stage.
Clinical research could be profoundly transformed by big data. Potential impacts include increased efficiency, improved patient engagement, predictive safety, and personalized therapy development. The strategic key to this lies in combining technology, talent, and governance.
Recommendations for practice:
Develop a big data roadmap: Define goals, pilot projects, and the long-term platform infrastructure.
Invest in talent: Recruit data scientists, AI experts, data engineers, and platform architects.
Establish partnerships: Collaborate with technology providers, start-ups, or academic institutions.
Strengthen governance and data protection: Establish clear guidelines on data use, consent, anonymization, and security.
Validate AI models: Use pilot projects to integrate AI models into study workflows and evaluate their effect on quality and costs.
What data sources are typically used in big data studies?
Electronic health records, registry data, biobanks, real-world evidence data (e.g., from apps and wearables), and molecular data, such as genomic data.
How big is the market for clinical data analysis platforms?
The market was worth around $5.9 billion in 2023 and is expected to grow significantly.
What is the potential of AI in clinical trials?
Very strong. The market for “AI in clinical trials” is expected to grow to over USD 22 billion by 2034. AI enables better identification of target groups, prediction of risky events, and adaptive study designs.
What are the data protection risks associated with big data in research?
GDPR compliance, informed consent, pseudonymization, transparent data governance, and the secure storage and use of sensitive medical data are all of great importance.
Which new roles will be particularly in demand in the pharmaceutical industry as a result of big data?
We are looking for data scientists, data engineers, AI specialists, clinical data managers, and platform architects with experience in healthcare.
Are you looking for qualified specialists and managers for data-driven projects in clinical research? BESTMINDS supports you with its specialized network. For over 15 years, we have been successfully placing candidates in the medical technology, healthcare, life sciences / pharma, and IT / media industries. We find exactly the candidates you need. Fairly, loyally, and discreetly. Whether you are looking for data scientists, clinical data managers, or AI architects. Contact us for a non-binding initial consultation so that we can fill your vacancies optimally and promptly.
